Zolpidem vs Zopiclone: How They Compare

Zolpidem and zopiclone are both "z-drugs": non-benzodiazepine sleeping tablets that act on the same GABA calming system as older sleeping pills, and both are prescribed for short-term insomnia. The practical difference is mostly about timing. Zolpidem is shorter-acting and aimed at trouble falling asleep, while zopiclone tends to last a little longer and is often chosen when the problem is staying asleep. But the more useful truth in the zolpidem vs zopiclone question is that these are close cousins, not rival cures. The guidelines treat them as broadly similar, short-term tools, and neither one resolves the pattern that keeps chronic insomnia running.

I want to be upfront about what this is and isn't. I'm a clinical psychologist, not your prescriber. I can't tell you which medication is right for you, and nothing here is a dosing instruction. What I can do is explain what the evidence actually says, and why the comparison matters less than it feels like it should.

Zolpidem vs zopiclone: what actually differs

Both drugs sit in the same pharmacological family, the non-benzodiazepine hypnotics, usually shortened to "z-drugs." They bind to much the same receptors that benzodiazepines do, produce a similar sedating effect, and the guidelines tend to discuss them together rather than as genuinely different treatments.

The differences people raise in the zopiclone vs zolpidem debate, which is stronger, which lasts longer, come down mostly to how long each stays active. Zolpidem clears relatively quickly, so it's framed around getting to sleep. Zopiclone lingers a little longer and is more associated with staying asleep, along with the metallic aftertaste some people notice. Neither fact makes one drug a categorically better answer than the other.

Here's the part that gets less airtime. When researchers pooled the registration-trial data for z-drugs submitted to the FDA, the drugs shortened the time to fall asleep by roughly 22 minutes compared with placebo, and a large share of even that modest effect was carried by the placebo response itself (Huedo-Medina et al., 2012). That is a meta-analysis of sleep-onset data, so it doesn't capture everything, but the signal is clear: the measurable benefit over a dummy pill is real and small. A more recent network meta-analysis of 154 trials reached a compatible conclusion, rating zolpidem and zopiclone as having a less favourable balance of benefit and tolerability than some newer agents for short-term treatment (De Crescenzo et al., 2022). That review's own caveat matters: most trials ran only weeks, many were industry-funded, and usable long-term data were thin across almost every drug.

What the guidelines actually say about z-drugs

Read the major insomnia guidelines and a consistent, sober theme emerges. The American Academy of Sleep Medicine could only issue weak, conditional recommendations for individual hypnotics, zolpidem included, because the evidence quality is low and the benefit over placebo is small. The same guideline recommends against common over-the-counter options such as melatonin, valerian and sedating antihistamines for chronic insomnia (Sateia et al., 2017). "Conditional" is guideline language for: this may help some people, short-term, and the decision should be shared with your prescriber.

The European guideline goes a step further on sequencing. It names cognitive behavioural therapy for insomnia, CBT-I, as the first-line treatment, and positions z-drugs and benzodiazepines as options for when CBT-I hasn't worked or isn't available, generally for no more than about four weeks, because tolerance can build within days to weeks and pushing the dose up accelerates dependence (Riemann et al., 2023). It's a consensus guideline, so the strength of individual recommendations varies, but the direction is unambiguous. The medication is the short-term adjunct. The psychological approach is the foundation.

Belsomra and Dayvigo: a newer mechanism

People comparing tablets eventually ask about the newer options: belsomra vs zopiclone, or dayvigo vs zopiclone. Belsomra (suvorexant) and Dayvigo (lemborexant) aren't z-drugs at all. Instead of broadly sedating the brain, they block orexin, one of the signals that keeps you awake. The idea is to turn wakefulness down rather than force sedation up.

Does that make them better than zopiclone? Honestly, it depends, and the evidence is still developing. The AASM gives suvorexant the same weak, conditional recommendation it gives the z-drugs (Sateia et al., 2017). The network meta-analysis mentioned earlier rated lemborexant among the more favourable agents on the balance of efficacy and tolerability for short-term use (De Crescenzo et al., 2022), but the same caveats apply: short trials, largely industry-funded, sparse long-term data. A different mechanism is not the same as a proven advantage. Which of these suits you, if any, is a prescriber's call, not a blog's.

What about zolpidem dosage?

Search for "zolpidem dosage" and you'll find numbers everywhere. I'm not going to add to them, and I'd gently push back on treating a dose as something to optimise on your own. Dosing is individualised for good clinical reasons: age, sex, other medications, liver function and how you responded last time all change the calculation. That is exactly the decision that belongs in a conversation with the person who prescribed it.

The stakes are clearest in older adults. A meta-analysis in people over 60 found that sedative hypnotics produced only a small improvement in sleep quality while roughly doubling to quadrupling the rate of side effects, including next-day grogginess, memory slips and impaired coordination (Glass et al., 2005). Those aren't abstract risks. They translate into falls, and into being less sharp than you feel.

So one plain safety line, for any of these drugs. If you feel drowsy, foggy or slowed the next morning, do not drive or operate anything that could hurt you until it fully clears, and flag the next-day effect with your prescriber. Feeling "fine" is not the same as being unimpaired.

The question underneath the comparison

Here's what I notice after years of this work. By the time someone is weighing zolpidem against zopiclone against Belsomra, the real problem usually isn't which molecule they take. It's that sleep has become something to solve, and the solving has become the engine. For most people, chronic insomnia is maintained less by a chemical deficit than by hyperarousal: a nervous system that treats being awake at 3am as a threat and works harder to fix it, which raises arousal, which pushes sleep further away. It's like drinking seawater when you're thirsty. Every sip feels like it should help. It's also why the next thing you reach for, a magnesium tablet, a new tea, rarely settles anything for long.

A tablet can quieten that loop for a while, and sometimes that's a reasonable short-term move. What it can't do is teach the system to stop bracing. Sleep runs on a body clock and a rising pressure to sleep, not on how hard you work at it, and effort is the one input that reliably makes it worse. That's the work the guidelines gesture at when they put CBT-I first (Riemann et al., 2023). The Insomnia Reset program is built on that same evidence base and adapts it for the arousal-and-anxiety mechanism specifically. It doesn't ask you to keep a nightly sleep diary, for instance, because for a hypervigilant sleeper, tracking every night tends to feed the very monitoring that keeps the loop running.

The reason most sleep advice fails is that it hands you one tool and expects it to work at every level of arousal. A calm-minute strategy is useless the moment you're wired. This is an arousal-matched approach: the program fits the tool to how activated you already are, rather than betting everything on a single trick.

One scope point, because it's care, not fine print. If your sleep problem might have a physical driver, loud snoring with gasping or pauses (possible sleep apnoea), an irresistible urge to move your legs at night (restless legs), or heavy daytime sleepiness a poor night doesn't explain, a sleeping tablet can mask it rather than treat it. Get that assessed by your GP first, so you're not aiming the wrong tool at the wrong target. If you want a low-pressure way to see where your own sleep is stuck, the Sleep Clarity quiz is a good starting point. It's an orientation tool, not a diagnosis.

If you're already taking one and want to stop

If you've been on zolpidem or zopiclone for a while and you're wondering how to come off, first: this is common, and it is not a failure. It's also not something to do abruptly on your own. Deprescribing guidelines recommend that people who've used these drugs longer than about four weeks, and most older adults, be offered a slow, planned taper rather than a sudden stop, because a gradual reduction improves the odds of stopping without serious harm (Pottie et al., 2018). What that taper looks like is a conversation to have with your prescriber. I won't script it here, and I'd be wary of anyone who hands you a schedule without knowing your history.

What I can tell you is what makes those attempts go better: the support matters as much as the schedule. In a randomised trial of older long-term users, combining a supervised taper with CBT-I produced a drug-free rate of around 85%, against roughly half for tapering or CBT alone (Morin et al., 2004). Even a plain-language education booklet moved the needle in a large trial: about 27% of older long-term users had stopped at six months, versus 5% on usual care (Tannenbaum et al., 2014). The psychological groundwork isn't a consolation prize for people who can't tolerate medication. It's often what makes coming off the medication stick.

The choice between two similar tablets is a smaller decision than it feels like at 3am. The larger one is what you build underneath it.

Common questions

Is zopiclone stronger than zolpidem?

Not in a simple stronger-or-weaker sense. They act on the same receptor system and produce broadly similar effects; the main practical difference is that zopiclone lasts a little longer while zolpidem clears faster (Huedo-Medina et al., 2012). "Stronger" usually just means "longer-acting" or "more familiar," and the right fit is a prescriber decision, not a ranking.

How long can you safely take zolpidem or zopiclone?

The guidelines frame these as short-term tools. The European guideline suggests generally no more than about four weeks, because tolerance can build within days to weeks and longer use raises the risk of dependence (Riemann et al., 2023). Longer use isn't automatically dangerous, but it's a reason to have a proper review with your prescriber rather than a repeat script on autopilot.

Is Belsomra or Dayvigo better than zopiclone?

They work by a different mechanism, blocking wakefulness rather than sedating, and a large network meta-analysis rated lemborexant (Dayvigo) favourably for short-term use, while suvorexant (Belsomra) carries the same conditional recommendation as the z-drugs (De Crescenzo et al., 2022; Sateia et al., 2017). "Better" depends on your situation, and the evidence is still short-term. It's a prescriber conversation.

What's a safe zolpidem dosage?

There's no single safe dose that fits everyone, which is exactly why I won't put a number here. The appropriate dose depends on your age, sex, other medications and health conditions, and older adults in particular are more prone to side effects at doses that look modest on paper (Glass et al., 2005). This is a question for the person who prescribes it.

Frequently asked questions

Is zopiclone stronger than zolpidem?

Not in a simple stronger-or-weaker sense. They act on the same receptor system and produce broadly similar effects; the main practical difference is that zopiclone lasts a little longer while zolpidem clears faster (Huedo-Medina et al., 2012). "Stronger" usually just means "longer-acting" or "more familiar," and the right fit is a prescriber decision, not a ranking.

How long can you safely take zolpidem or zopiclone?

The guidelines frame these as short-term tools. The European guideline suggests generally no more than about four weeks, because tolerance can build within days to weeks and longer use raises the risk of dependence (Riemann et al., 2023). Longer use isn't automatically dangerous, but it's a reason to have a proper review with your prescriber rather than a repeat script on autopilot.

Is Belsomra or Dayvigo better than zopiclone?

They work by a different mechanism, blocking wakefulness rather than sedating, and a large network meta-analysis rated lemborexant (Dayvigo) favourably for short-term use, while suvorexant (Belsomra) carries the same conditional recommendation as the z-drugs (De Crescenzo et al., 2022; Sateia et al., 2017). "Better" depends on your situation, and the evidence is still short-term. It's a prescriber conversation.

What's a safe zolpidem dosage?

There's no single safe dose that fits everyone, which is exactly why I won't put a number here. The appropriate dose depends on your age, sex, other medications and health conditions, and older adults in particular are more prone to side effects at doses that look modest on paper (Glass et al., 2005). This is a question for the person who prescribes it.